EP1456347A4 - Anticorps se liant a blys selon un mode immunospecifique - Google Patents

Anticorps se liant a blys selon un mode immunospecifique

Info

Publication number
EP1456347A4
EP1456347A4 EP02802570A EP02802570A EP1456347A4 EP 1456347 A4 EP1456347 A4 EP 1456347A4 EP 02802570 A EP02802570 A EP 02802570A EP 02802570 A EP02802570 A EP 02802570A EP 1456347 A4 EP1456347 A4 EP 1456347A4
Authority
EP
European Patent Office
Prior art keywords
blys
antibodies
immunospecifically bind
immunospecifically
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02802570A
Other languages
German (de)
English (en)
Other versions
EP1456347A2 (fr
Inventor
Steven M Ruben
Steven C Barash
Gil H Choi
Tristan J Vaughan
David Hilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1456347A2 publication Critical patent/EP1456347A2/fr
Publication of EP1456347A4 publication Critical patent/EP1456347A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP02802570A 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique Withdrawn EP1456347A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US331469P 2001-11-16
US34081701P 2001-12-19 2001-12-19
US340817P 2001-12-19
PCT/US2002/036496 WO2003055979A2 (fr) 2001-11-16 2002-11-14 Anticorps se liant à blys selon un mode immunospécifique

Publications (2)

Publication Number Publication Date
EP1456347A2 EP1456347A2 (fr) 2004-09-15
EP1456347A4 true EP1456347A4 (fr) 2006-08-02

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02802570A Withdrawn EP1456347A4 (fr) 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique

Country Status (4)

Country Link
EP (1) EP1456347A4 (fr)
AU (1) AU2002364954A1 (fr)
CA (1) CA2467521A1 (fr)
WO (1) WO2003055979A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
PL198934B1 (pl) 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DK1210425T4 (en) 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
KR20060027801A (ko) 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2267034A3 (fr) * 2004-03-31 2011-06-22 Canon Kabushiki Kaisha Protéine de liaison or et utilisation en conséquence
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP5570681B2 (ja) * 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
ES2422479T3 (es) * 2007-03-27 2013-09-11 Zymogenetics Inc Combinación de inhibición de BLyS y micofenolato de mofetilo para tratamiento de enfermedades autoinmunitarias
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2200631A1 (fr) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
CN103421113B (zh) 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
WO2018006824A1 (fr) * 2016-07-06 2018-01-11 上海开拓者生物医药有限公司 Anticorps de blys, son procédé de préparation et son application
EP3576790A4 (fr) 2017-02-01 2020-12-23 Yale University Traitement de la résistance aux diurétiques
BR112020013519A2 (pt) 2018-01-05 2020-12-01 Corvidia Therapeutics, Inc método para tratamento de uma inflamação.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060397A1 (fr) * 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
WO2001087977A2 (fr) * 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
WO2002002641A1 (fr) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533997A (ja) * 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060397A1 (fr) * 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
WO2001087977A2 (fr) * 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
WO2002002641A1 (fr) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GROSS J A ET AL: "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 404, 27 April 2000 (2000-04-27), pages 995 - 999, XP002140939, ISSN: 0028-0836 *
GROSS J A; ET AL: "TACI-IG Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLYS", IMMUNITY, vol. 15, August 2001 (2001-08-01), pages 289 - 302, XP003008630 *
SCHNEIDER P ET AL: "BAFF, A NOVEL LIGAND OF THE TUMOR NECROSIS FACTOR FAMILY, STIMULATES B CELL GROWTH", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747 - 1756, XP000915409, ISSN: 0022-1007 *
SHU H-B ET AL: "TALL-1 IS A NOVEL MEMBER OF THE TNF FAMILY THAT IS DOWN-REGULATED BY MITOGENS", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 65, no. 5, May 1999 (1999-05-01), pages 680 - 683, XP000939092, ISSN: 0741-5400 *
WU Y; ET AL: "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 45, 10 November 2000 (2000-11-10), pages 35478 - 35485, XP002367757 *
ZHOU T ET AL: "THERAPEUTIC POTENTIAL OF ANTAGONIZING BLYS FOR CHRONIC LYMPHOCYTIC LEUKEMIA", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 98, no. 11, PART 1, 16 November 2001 (2001-11-16), pages 808A, XP009041133, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
AU2002364954A8 (en) 2003-07-15
WO2003055979A2 (fr) 2003-07-10
CA2467521A1 (fr) 2003-07-10
AU2002364954A1 (en) 2003-07-15
WO2003055979A3 (fr) 2003-12-18
EP1456347A2 (fr) 2004-09-15

Similar Documents

Publication Publication Date Title
AU2002364954A8 (en) Antibodies that immunospecifically bind to blys
CY2012003I1 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
EP1465925A4 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
HK1075470A1 (en) Antibodies that immunospecifically bind to trail receptors
EP1572874A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs de trail
IL213564A0 (en) Antibodies to vla-1
IL235116A0 (en) Antibodies to opgl (osteoprotegerin ligand)
GB0417384D0 (en) Antibodies to c-met
IL173965A0 (en) Peptides and compounds that bind to thrombopoietin receptors
AU2002359659A8 (en) Cross reference to related application
AU2003234706A8 (en) Antibodies that specifically bind to tl5
AU2003240822A8 (en) Antibodies that specifically bind to neurokinin b
AU2003256299A8 (en) Antibodies that specifically bind to reg iv
AU2003218456A1 (en) Antibodies that specifically bind to gmad
AU2002351374A8 (en) Antibodies to treat cancer
AU2003302822A8 (en) Antibodies to treat cancer
EP1633316A4 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
AU2003288809A8 (en) Peptides that bind of the vegfr-2
EP1339426A4 (fr) Anticorps a liaison immunospecifique avec les recepteurs "trail"
AU2003259835A8 (en) Antibodies that immunospecifically bind to trail receptors
AU2003228483A8 (en) Antibodies that specifically bind to tr2
EP1393746A4 (fr) Compositions d'anticorps polyclonaux humains

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 5/12 B

Ipc: 7C 12N 15/86 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 07H 21/04 A

A4 Supplementary search report drawn up and despatched

Effective date: 20060704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20060628BHEP

Ipc: A61P 37/06 20060101ALI20060628BHEP

Ipc: A61K 39/395 20060101ALI20060628BHEP

Ipc: C07K 16/28 20060101ALI20060628BHEP

Ipc: C12N 5/10 20060101ALI20060628BHEP

Ipc: C12N 15/13 20060101ALI20060628BHEP

Ipc: C12N 5/12 20060101ALI20060628BHEP

Ipc: C12N 15/86 20060101ALI20060628BHEP

Ipc: C12N 15/85 20060101ALI20060628BHEP

Ipc: C07H 21/04 20060101AFI20040921BHEP

17Q First examination report despatched

Effective date: 20070710

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080122